Obesity

Original Article CLINICAL TRIALS: BEHAVIOR, PHARMACOTHERAPY, DEVICES, SURGERY

Canagliflozin: Effects in Overweight and Obese Subjects Without Diabetes Mellitus Harold E. Bays1, Richard Weinstein2, Gordon Law3 and William Canovatchel3

Objective: To evaluate the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on body weight in overweight and obese subjects (body mass index [BMI] 27 and

Canagliflozin: effects in overweight and obese subjects without diabetes mellitus.

To evaluate the effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, on body weight in overweight and obese subjects (body mass inde...
274KB Sizes 0 Downloads 0 Views
Download PDF

Recommend Documents

Behaviour modification in obese subjects with type 2 diabetes mellitus.
Canagliflozin Treatment in Patients with Type 2 Diabetes Mellitus.
[Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus].
Circulating Adipokines in Healthy versus Unhealthy Overweight and Obese Subjects.
Effects of canagliflozin on cardiovascular risk factors in patients with type 2 diabetes mellitus.
Canagliflozin: A Novel SGLT2 Inhibitor for Type 2 Diabetes Mellitus.
Accelerated starvation in late pregnancy: a comparison between obese women with and without gestational diabetes mellitus.
High protein weight loss diets in obese subjects with type 2 diabetes mellitus.
The effect of slow spaced eating on hunger and satiety in overweight and obese patients with type 2 diabetes mellitus.
A systematic review of commercial weight loss programmes' effect on glycemic outcomes among overweight and obese adults with and without type 2 diabetes mellitus.

Follow Us

Copyright © 2024 D.DOCKSCI.COM. All rights reserved. | Design by w3layouts